Xaira Therapeutics
AI-native biotechnology company developing models, experimental systems, and drug programs for therapeutics.
Website: https://www.xaira.com/
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Name | Xaira Therapeutics |
| Tagline | AI-native biotechnology company developing models, experimental systems, and drug programs for therapeutics. [xaira.com, retrieved 2024] |
| Headquarters | South San Francisco, California, US [Crunchbase, retrieved 2024] |
| Founded | 2024 [Crunchbase, retrieved 2024] |
| Stage | Series A [Crunchbase, retrieved 2024] |
| Business Model | Other |
| Industry | Deeptech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding Label | $100M+ |
| Total Disclosed | ~$1,000,000,000 [GeekWire, April 2024] |
Links
Publicly reported
- Website: https://www.xaira.com/
- LinkedIn: https://www.linkedin.com/company/xaira-therapeutics/
Summary and Signal
PUBLIC Xaira Therapeutics is an AI-native biotech building models, experimental systems, and internal drug programs across target discovery, molecular design, and clinical development, and it merits investor attention because it launched at unusual scale, with more than $1 billion in disclosed financing behind a platform bet that aims to pair frontier AI with in-house therapeutics execution [GeekWire, April 2024] [PharmaPhorum, April 2024]. The founding story is less a typical software spinout than a coordinated incubation between ARCH Venture Partners and Foresite Labs, drawing its initial scientific foundation from protein-design work associated with David Baker’s lab at the University of Washington’s Institute for Protein Design, including RFdiffusion and RFantibody [GeekWire, April 2024] [PharmaPhorum, April 2024].
Public materials describe the product stack as a set of linked systems rather than a standalone software SKU: Xaira says it uses AI to identify therapeutic targets, design new medicines, and identify patients most likely to benefit; later disclosures add X-Design for antibody design, X-Cell for virtual-cell modeling, and X-Patient for clinical development workflows [xaira.com, retrieved 2024] [FierceBiotech, October 2026] [xaira.com, March 2026]. The differentiating claim, according to company and trade-press sources, is that Xaira is trying to connect model development, proprietary biological data, and wet-lab drug creation inside one organization, with an emphasis on protein and antibody therapeutics for historically difficult targets rather than selling tools alone [Greenhouse, retrieved 2026] [GeekWire, April 2024].
The team is one reason the company has drawn immediate institutional attention: Baker is a University of Washington professor who shared the 2024 Nobel Prize in Chemistry, Hetu Kamisetty previously worked at Meta and Baker’s institute, and launch leadership included Marc Tessier-Lavigne, formerly Genentech CSO and later identified in multiple public profiles as Xaira’s CEO or founding CEO [TechCrunch, October 2024] [GeekWire, April 2024] [The AI Insider, April 2024] [LinkedIn, retrieved 2026]. On capitalization, the public record is clear on scale but thinner on structure, with launch reporting describing more than $1 billion in financing and naming a syndicate that included ARCH, Foresite, F-Prime, NEA, Sequoia, Lux, Lightspeed, Menlo, Two Sigma Ventures, and others; the company appears positioned as a venture-scale therapeutics developer rather than an enterprise SaaS vendor [GeekWire, April 2024] [PharmaPhorum, April 2024].
For the next 12 to 18 months, the key public checkpoints are whether Xaira can translate platform claims into repeatable pipeline output, sharpen evidence around assets such as XA-1 and XA-4, and show that model-led design compresses development cycles in ways that matter biologically, not just computationally [FierceBiotech, October 2026]. Hiring signals, including roles spanning functional genomics, portfolio strategy, business development, and operations, suggest the company is still building both scientific depth and alliance capacity, which fits a platform intended to mature into a multi-asset therapeutics engine [Greenhouse, retrieved 2026] [Menlo Ventures, retrieved 2026] [F-Prime Capital, retrieved 2026] [SportsTechJobs, retrieved 2026].
One source, partially checked -- Relies on a mix of independent reporting, company materials, and public profiles; financing is well corroborated, while product and platform details are partly company-described.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | Other |
| Industry / Vertical | Deeptech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | $100M+ (total disclosed ~$1,000,000,000) |
Company Overview
PUBLIC
Xaira Therapeutics entered the market in 2024 from an unusual starting point: it launched already capitalized at a scale more typical of a later-stage platform company than a newly formed biotech [xaira.com, retrieved 2024] [Crunchbase, retrieved 2024]. In plain terms, the company presents itself as an AI-native therapeutics business, built to develop models, experimental systems, and internal drug programs rather than sell standalone software [xaira.com, retrieved 2024]. Public company materials place headquarters in South San Francisco, California, and Crunchbase lists the business as founded in 2024 [xaira.com, retrieved 2024] [Crunchbase, retrieved 2024].
The chronology that can be supported from company and database records is still short, but it is already instructive. Xaira appeared publicly in 2024 with a company website describing an approach that uses AI to identify therapeutic targets, design medicines, and identify patients most likely to benefit [xaira.com, retrieved 2024]. Crunchbase records a Series A financing in April 2024 and attributes approximately $1.0 billion of disclosed funding to that launch round, which aligns with the scale described in the company’s early public profile [Crunchbase, retrieved 2024]. By March 2026, the company had added a named platform milestone, announcing X-Cell, described as its first virtual cell model trained on the X-Atlas/Pisces perturbation dataset [xaira.com, March 2026].
What is visible in public filings and company materials, then, is a company that formed quickly around a large capital base and a broad platform ambition, with early emphasis on internal therapeutic discovery infrastructure rather than commercial deployment claims [xaira.com, retrieved 2024] [Crunchbase, retrieved 2024] [xaira.com, March 2026]. The legal entity details beyond the operating company name are not established in the provided company website and Crunchbase materials, so the cleaner read is to treat Xaira today as a well-funded private therapeutics platform headquartered in South San Francisco and still early in its public operating history [xaira.com, retrieved 2024] [Crunchbase, retrieved 2024].
Well sourced -- Confirmed by Crunchbase and the company website.
The Product and the Stack
MIXED
The product story is unusually clear at the highest level and still early at the asset level. Xaira describes itself as an AI-native therapeutics company that uses AI to identify therapeutic targets, design new medicines, and identify patients most likely to benefit, which places the company closer to an integrated drug developer than to a standalone software vendor [xaira.com, retrieved 2024] [GeekWire, April 2024]. Public reporting ties the initial technical foundation to RFdiffusion and RFantibody, protein-design models developed at the University of Washington's Institute for Protein Design, and links that scientific base directly to David Baker's lab [PharmaPhorum, April 2024].
The disclosed platform now appears to be organized into at least four layers. X-Design is described as an antibody-design platform intended to generate "drug-ready" antibodies for Xaira's internal pipeline [FierceBiotech, October 2026] [Partnology]. X-Cell is described as a virtual cell model designed to predict the effects of genetic perturbations, and Xaira said in March 2026 that it was trained on the X-Atlas/Pisces genome-wide perturbation dataset [xaira.com, March 2026]. X-Patient is presented as the link between biological models and patient selection in clinical development, while X-Scientist is framed by the company as an AI co-scientist that supports computational workflows and scientific investigation across discovery [FierceBiotech, October 2026] [xaira.com, retrieved 2024].
The evidence for technical progress is promising but still mostly company-directed or early press reporting. FierceBiotech reported in October 2026 that Xaira had disclosed two early pipeline assets, XA-1 and XA-4, with XA-1 described as a cancer candidate created from scratch in seven weeks and XA-4 aimed at a difficult G-protein-coupled receptor [FierceBiotech, October 2026]. That suggests the company is trying to show that its models can move beyond target ideation into lead generation for hard biology, but the public record does not yet establish clinical validation, external customer adoption, or comparative success rates versus other AI-biotech platforms [FierceBiotech, October 2026] [GeekWire, April 2024]. Some hiring signals are directionally useful rather than conclusive: roles in functional genomics, portfolio strategy, business development, and operations support a view that Xaira is building a full-stack discovery organization, and any deeper assumptions about internal tooling or infrastructure should be treated as tech-stack inference from job postings rather than verified architecture [Greenhouse, retrieved 2026] [Menlo Ventures, retrieved 2026] [F-Prime Capital, retrieved 2026] [SportsTechJobs, retrieved 2026].
No independent source found -- This section relies materially on company website statements and company-linked disclosures, with partial support from GeekWire, PharmaPhorum, and FierceBiotech.
The Market They Are Entering
PUBLIC
The market matters now because Xaira sits at the intersection of two capital-intensive sectors, drug discovery and applied AI, where investors are paying for the chance that better models can shorten expensive biological iteration rather than merely automate desk work [GeekWire, April 2024] [PharmaPhorum, April 2024].
Public sources in hand do not provide a named third-party TAM, SAM, or SOM for Xaira specifically, so the safer read is qualitative. The company is being built as an integrated therapeutics platform, not a software vendor, with activity spanning target identification, molecular design, and patient selection [xaira.com, retrieved 2024] [GeekWire, April 2024]. That places its addressable market closer to the economics of biopharma R&D and eventual drug commercialization than to a narrow market for research software seats, even if AI is the enabling layer rather than the end product [xaira.com, retrieved 2024] [PharmaPhorum, April 2024].
The demand signal visible in public reporting is less about current customer spend and more about where large pools of capital are willing to underwrite platform risk. Xaira launched with more than $1 billion in financing in April 2024, with ARCH Venture Partners and Foresite Labs central to incubation and a long investor roster behind the syndicate [GeekWire, April 2024] [PharmaPhorum, April 2024]. That does not prove end-market adoption, but it does show that investors see a large enough opportunity in AI-enabled therapeutics to support unusually heavy upfront spend before clinical proof.
The nearest adjacent markets are computational biology tools, antibody and protein therapeutics discovery, and clinical stratification infrastructure. Xaira's own public positioning spans all three: it says it uses AI to identify therapeutic targets, design medicines, and identify patients most likely to benefit [xaira.com, retrieved 2024]. Its technical foundation reportedly draws from RFdiffusion and RFantibody, while later product disclosures added X-Design for antibody design, X-Cell for virtual-cell modeling, and X-Patient for clinical development support, which suggests the company is pursuing value capture across several points in the drug-development stack rather than a single workflow tool [PharmaPhorum, April 2024] [FierceBiotech, October 2026] [xaira.com, March 2026].
The main tailwind is that historically difficult targets remain commercially attractive if a platform can improve hit generation and optimization speed. Xaira's hiring and product descriptions repeatedly emphasize protein and antibody therapeutics for difficult molecular targets, and later reporting tied that approach to early assets including XA-1 and XA-4 [Greenhouse, retrieved 2026] [FierceBiotech, October 2026]. The regulatory and macro constraint is that no amount of model performance removes the need for preclinical validation, manufacturing, and clinical evidence, so market expansion for companies like Xaira still depends on conversion from computational promise to drug candidates that survive standard biotech gating steps [FierceBiotech, October 2026] [GeekWire, April 2024].
| Market lens | Public evidence | Relevance to Xaira |
|---|---|---|
| Integrated therapeutics platform | Xaira is described as using AI across target discovery, molecular design, and patient identification [xaira.com, retrieved 2024] | Suggests a broader addressable opportunity than research software alone |
| AI-enabled drug discovery capital formation | Xaira launched with more than $1 billion in financing [GeekWire, April 2024] | Indicates investor belief that the category can support very large company formation at inception |
| Difficult-target biologics discovery | Public materials point to protein and antibody therapeutics, especially hard molecular targets [Greenhouse, retrieved 2026] [PharmaPhorum, April 2024] | Frames Xaira against high-value discovery programs rather than generic AI tooling |
| Clinical-development adjacency | X-Patient is described as linking biological models with patient selection and clinical development [FierceBiotech, October 2026] | Expands potential scope into downstream development decisions |
The evidence supports a market thesis built on breadth of workflow and biology ownership, not on a cited market-size figure. For investors, that is constructive, but still early: the category is clearly financeable, while commercial and clinical proof remain the harder market tests.
One source, partially checked -- Section relies on named public sources including GeekWire, PharmaPhorum, Xaira's website, Greenhouse, and FierceBiotech, but it contains no independently corroborated third-party market-sizing figures and several product-scope claims are company or single-publisher sourced.
The Competitive Field
Market map
MIXED Xaira is positioned less against a single named software rival than against three alternative ways biopharma already buys progress: internal discovery teams, AI-enabled discovery platforms, and venture-backed therapeutics builders that pair computation with wet lab execution [GeekWire, April 2024] [xaira.com, retrieved 2024].
The public record here is unusually thin on explicit competitor naming, which matters in itself. Available sources describe Xaira as an integrated therapeutics company built to identify targets, design medicines, and match patients, rather than as a standalone software vendor selling seats into pharma R&D [GeekWire, April 2024] [xaira.com, retrieved 2024]. That places its nearest practical alternatives in three buckets: large pharmaceutical research organizations with in-house computational biology groups, AI-first drug discovery companies pursuing internal pipelines, and specialist model providers that can contribute pieces of the workflow without owning the full development stack [PharmaPhorum, April 2024] [FierceBiotech, October 2026].
What stands out is that Xaira appears to be competing for scientific throughput and asset quality, not merely model performance. The company says its platform spans X-Design for antibody design, X-Cell for virtual-cell modeling, X-Patient for patient selection and clinical development, and X-Scientist as an AI co-scientist layer [FierceBiotech, October 2026] [xaira.com, March 2026] [xaira.com, retrieved 2024]. If that stack works as described, the more relevant substitute is the conventional biopharma process of stitching together target biology, molecular design, translational work, and early development across separate teams and tools, rather than any one point competitor.
Edge and durability
MIXED Xaira's edge, based on public evidence, rests on a rare combination of capital, scientific pedigree, and control over an internal development agenda.
Capital is the clearest near-term advantage. The company launched with more than $1 billion in financing, with ARCH Venture Partners and Foresite Labs as joint incubators and a syndicate that included F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed, Menlo Ventures, Two Sigma Ventures, the Parker Institute for Cancer Immunotherapy, Byers Capital, Rsquared, and SV Angel [GeekWire, April 2024] [PharmaPhorum, April 2024]. In a category where the constraint is often the cost of building experimental systems around ambitious models, that balance sheet gives Xaira room to build datasets, recruit senior operators, and carry internal programs longer than a thinner-capitalized peer could.
The second edge is talent concentration around a specific scientific starting point. Public reporting ties the founding technology to David Baker's lab at the University of Washington's Institute for Protein Design, including RFdiffusion and RFantibody, while also placing Hetu Kamisetty, formerly of Meta and the Institute for Protein Design, in a founding role [PharmaPhorum, April 2024] [GeekWire, April 2024]. Marc Tessier-Lavigne's role as founding CEO, alongside executives with Genentech backgrounds, suggests an attempt to bridge frontier model development with drug development discipline [The AI Insider, April 2024] [LinkedIn]. That edge is meaningful, but only partly durable. Reputation and recruitment help early; over an 18-month window, the moat becomes more perishable unless it compounds into proprietary data, validated platform outputs, or differentiated assets.
Exposure points
MIXED The main exposure is that Xaira has chosen the hardest lane in the category: an integrated therapeutics model that must eventually prove not just model novelty, but program selection, wet-lab execution, and development judgment.
Publicly disclosed progress helps, but it does not yet close that gap. FierceBiotech reported in October 2026 that Xaira disclosed two early pipeline assets, XA-1 and XA-4, with XA-1 described as a cancer candidate created from scratch in seven weeks and XA-4 aimed at a difficult G-protein-coupled receptor [FierceBiotech, October 2026]. Those are useful competitive signals because they move the story from platform ambition to named programs. Still, they remain early. A rival with clinical validation or a deeper partnership channel into large pharma would hold a clearer commercial advantage than Xaira can yet claim from public sources.
Xaira is also exposed to adjacent specialists that can win without owning the full stack. A focused model provider or a biotech with a narrower disease thesis can move faster in a single domain, while incumbent pharma can absorb external tools and keep downstream economics in-house. Xaira's own hiring mix points to this tension: roles in functional genomics, portfolio strategy, procurement, and business development indicate platform building plus organizational expansion, but they also underline the breadth of execution required [Greenhouse, retrieved 2026] [SportsTechJobs, retrieved 2026] [Menlo Ventures, retrieved 2026] [F-Prime Capital, retrieved 2026]. Breadth can become an advantage, though before clinical proof it also broadens the surface area for competitive slippage.
Plausible 18-month scenario
MIXED The most plausible near-term competitive outcome is a sorting event based on whether integrated AI biotechs can turn internal platforms into externally legible asset quality.
If Xaira can continue disclosing pipeline assets and show that systems such as X-Design and X-Cell produce candidates or biological insights faster than conventional discovery, it is one of the better-positioned names to gain share of investor attention, recruiting power, and future partnership interest, largely because few peers started with this level of capital and institutional support [GeekWire, April 2024] [FierceBiotech, October 2026]. In that scenario, Xaira is the winner if capital plus scientific depth converts into reproducible development milestones.
The likely loser if the opposite happens is not a named company from the current source set, but the broader class of fully integrated AI-native biotech builders that have raised ahead of clinical validation. If platform claims across the sector continue to outpace public evidence of differentiated assets, incumbent pharma R&D organizations and narrower specialist toolmakers could retain the upper hand by default. For Xaira specifically, the next 18 months appear less about beating a single branded rival and more about proving that an expensive, vertically integrated approach can produce program-level evidence that simpler substitutes cannot match [xaira.com, retrieved 2024] [FierceBiotech, October 2026].
Opportunity
PUBLIC
The prize here is unusually large: if Xaira can turn its integrated stack of biological data, foundation models, and in-house drug programs into a repeatable engine for producing differentiated therapeutics, it could mature into a top-tier AI-native biotech platform rather than a single-asset drug company [xaira.com, retrieved 2024] [GeekWire, April 2024] [PharmaPhorum, April 2024].
The headline opportunity is not software revenue alone. Public materials describe Xaira as an integrated therapeutics company using AI to identify targets, design medicines, and match patients to treatments, with the initial technical base drawn from David Baker lab work such as RFdiffusion and RFantibody, and with more than $1 billion in launch financing behind the effort [xaira.com, retrieved 2024] [PharmaPhorum, April 2024] [GeekWire, April 2024]. That combination matters because it gives the company a plausible route to owning more of the value chain: model development, wet-lab validation, pipeline creation, and eventually clinical positioning, rather than stopping at a tools layer [FierceBiotech, October 2026] [xaira.com, March 2026]. The public record is still early, but the disclosure of X-Design, X-Cell, X-Patient, and the first named assets XA-1 and XA-4 makes the upside case more concrete than an abstract platform story [FierceBiotech, October 2026] [xaira.com, March 2026].
The clearest public paths to scale break into a few distinct scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| AI-native drug engine | Xaira repeatedly generates internal drug candidates against hard targets and becomes known as a multi-program biotech platform | Additional preclinical disclosures or early clinical advancement from programs such as XA-1 and XA-4 [FierceBiotech, October 2026] | The company has already disclosed two internal assets and an antibody design system intended to feed its own pipeline [FierceBiotech, October 2026] |
| Foundational model owner for biology | X-Cell and related models become core internal infrastructure for target selection, perturbation analysis, and patient stratification, improving hit rates across programs | Broader use of the X-Atlas/Pisces-trained X-Cell model across discovery and development workflows [xaira.com, March 2026] | Xaira has publicly framed X-Cell as a virtual-cell model trained on a large genome-wide perturbation dataset, which is consistent with a reusable internal model layer rather than a one-off asset tool [xaira.com, March 2026] [cdn.xaira.com, retrieved 2026] |
| Selective partnering platform | Xaira keeps internal ownership of crown-jewel programs while partnering parts of the platform or specific assets with larger biopharma | Hiring of a vice president for business development and alliance management [Menlo Ventures, retrieved 2026] | The company is building business development capability, and platform biotechs often use partnerships to finance pipeline expansion without giving up the entire stack [Menlo Ventures, retrieved 2026] [GeekWire, April 2024] |
What compounding looks like is straightforward in theory, though still unproven in public data. Better models should improve target selection and molecular design; those programs should generate more experimental data; that data should refine the next generation of models; and a stronger pipeline should attract more senior talent, more partnership interest, and more capital efficiency per program over time [xaira.com, retrieved 2024] [xaira.com, March 2026] [FierceBiotech, October 2026]. There are early signs of the ingredients for that flywheel: the company says it operates across target discovery, molecular design, and patient selection; it has launched X-Cell on top of a large perturbation dataset; and its hiring spans functional genomics, portfolio strategy, procurement for operations and AI, and business development, which suggests an organization being built for a full-stack therapeutics motion rather than a narrow research tool effort [xaira.com, retrieved 2024] [xaira.com, March 2026] [Greenhouse, retrieved 2026] [SportsTechJobs, retrieved 2026] [F-Prime Capital, retrieved 2026] [Menlo Ventures, retrieved 2026].
The size of the win is difficult to anchor precisely because public market comparables move with the biotech cycle and the company is preclinical in the evidence set here. Still, the launch financing itself sets a useful floor for ambition: investors including ARCH Venture Partners, Foresite Labs, F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed, Menlo, and others backed the company with more than $1 billion at launch, an unusually large capital base for a newly unveiled biotech platform [GeekWire, April 2024] [PharmaPhorum, April 2024]. If the "AI-native drug engine" scenario plays out, meaning Xaira demonstrates that its model stack can repeatedly produce valuable internal programs and selective partnerships, the outcome could support a multi-billion-dollar enterprise value (scenario, not a forecast), because the company would be valued not as a single-asset bet but as a platform with multiple shots on goal and proprietary data compounding across programs [GeekWire, April 2024] [FierceBiotech, October 2026] [xaira.com, March 2026]. That is the core upside case the market will likely test over the next several years.
One source, partially checked -- This section relies on a mix of independent reporting from GeekWire, PharmaPhorum, and FierceBiotech, plus company materials for platform claims and X-Cell details.
Sources
Publicly reported
[xaira.com, retrieved 2024] Xaira Therapeutics | AI-Powered Drug Discovery & Development | https://www.xaira.com/
[Crunchbase, retrieved 2024] Xaira Therapeutics | Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/xaira-therapeutics
[GeekWire, April 2024] Inside the Seattle labs of Xaira, the AI-powered startup launched with $1B from investors | https://www.geekwire.com/2024/inside-the-seattle-labs-of-xaira-the-ai-powered-startup-launched-with-1b-from-investors/
[PharmaPhorum, April 2024] Enter Xaira, with $1bn for its AI in drug discovery platform | https://pharmaphorum.com/news/enter-xaira-1bn-its-ai-drug-discovery-platform
[FierceBiotech, October 2026] We’ve been taking our time: Xaira reveals antibody platform and first taste of pipeline | https://www.fiercebiotech.com/biotech/weve-been-taking-our-time-xaira-reveals-antibody-platform-and-first-taste-pipeline
[xaira.com, March 2026] Xaira Therapeutics Launches X-Cell, Its First Virtual Cell Model, Trained on the Largest-Ever Genome-Wide Perturbation Dataset, X-Atlas/Pisces | https://www.xaira.com/news/xaira-therapeutics-launches-x-cell-its-first-virtual-cell-model-trained-on-the-largest-ever-genome-wide-perturbation-dataset-x-atlas-pisces
[Greenhouse, retrieved 2026] Scientist I/II, Functional Genomics | https://job-boards.greenhouse.io/xairatherapeutics/jobs/5198737007
[TechCrunch, October 2024] DeepMind's Demis Hassabis and John Jumper scoop Nobel Prize in Chemistry for AlphaFold | https://techcrunch.com/2024/10/09/deepminds-demis-hassabis-and-john-jumper-scoop-nobel-prize-in-chemistry-for-alphafold/
[The AI Insider, April 2024] AI Biotech Xaira Grabs $1 Billion to Re-Engineer Drug Development | https://theaiinsider.tech/2024/04/24/ai-biotech-xaira-grabs-1-billion-to-re-engineer-drug-development/
[LinkedIn, retrieved 2026] Xaira Therapeutics | LinkedIn | https://www.linkedin.com/company/xaira-therapeutics/
[Menlo Ventures, retrieved 2026] Vice President, Business Development and Alliance Management | https://jobs.menlovc.com/companies/xaira-therapeutics/jobs/89121833-vice-president-business-development-and-alliance-management
[F-Prime Capital, retrieved 2026] Principal Scientist, Target Discovery & Portfolio Strategy | https://jobs.fprimecapital.com/companies/xaira-therapeutics/jobs/96874031-principal-scientist-target-discovery-portfolio-strategy
[SportsTechJobs, retrieved 2026] Procurement Business Partner, Operations & AI | https://sportstechjobs.com/procurement-business-partner-operations-and-ai-xaira/6ad80146c3681d7ff25f0908
Articles about Xaira Therapeutics
- Xaira Therapeutics Launched With $1 Billion to Design Antibodies in Weeks — The biotech, incubated by ARCH and Foresite, is betting its integrated AI models can compress years of discovery into months for difficult targets.